# CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors

> **NCT07179692** · PHASE1 · RECRUITING · sponsor: **Chongqing Precision Biotech Co., Ltd** · enrollment: 108 (estimated)

## Conditions studied

- Lung Cancer
- Gastric Cancer
- Colon Cancer
- Rectal Cancer
- Esophageal Cancer
- Pancreas Cancer

## Interventions

- **BIOLOGICAL:** CEA-targeted CAR-T cells
- **BIOLOGICAL:** CEA-targeted CAR-T cells
- **BIOLOGICAL:** CEA-targeted CAR-T cells

## Key facts

- **NCT ID:** NCT07179692
- **Lead sponsor:** Chongqing Precision Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-12
- **Primary completion:** 2028-03-31
- **Final completion:** 2028-05-31
- **Target enrollment:** 108 (ESTIMATED)
- **Last updated:** 2025-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07179692

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07179692, "CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07179692. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*